Nguyen Thi Hiep, Liu Xiaoming, Su Zhen Zhong, Hsu Alan Chen-Yu, Foster Paul S, Yang Ming
Priority Research Centre for Healthy Lungs, The University of Newcastle, Callaghan, NSW, Australia.
Faculty of Health and Medicine, School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
Front Immunol. 2018 Jul 4;9:1541. doi: 10.3389/fimmu.2018.01541. eCollection 2018.
Influenza is a major health burden worldwide and is caused by influenza viruses that are enveloped and negative stranded RNA viruses. Little progress has been achieved in targeted intervention, either at a population level or at an individual level (to treat the cause), due to the toxicity of drugs and ineffective vaccines against influenza viruses. MicroRNAs (miRNAs) are small non-coding RNAs that play critical roles in gene expression, cell differentiation, and tissue development and have been shown to silence viral replication in a sequence-specific manner. Investigation of these small endogenous nucleotides may lead to new therapeutics against influenza virus infection. Here, we describe our current understanding of the role of miRNAs in host defense response against influenza virus, as well as their potential and limitation as new therapeutic approaches.
流感是全球主要的健康负担,由包膜的负链RNA病毒即流感病毒引起。由于药物的毒性以及针对流感病毒的疫苗效果不佳,无论是在人群层面还是个体层面(治疗病因),靶向干预方面都进展甚微。微小RNA(miRNA)是一类小的非编码RNA,在基因表达、细胞分化和组织发育中发挥关键作用,并且已证明其能以序列特异性方式使病毒复制沉默。对这些内源性小核苷酸的研究可能会带来针对流感病毒感染的新疗法。在此,我们阐述了目前对miRNA在宿主抗流感病毒防御反应中的作用的理解,以及它们作为新治疗方法的潜力和局限性。